Fe_001
Lv62
2330 积分
2022-10-17 加入
-
[2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis]
3个月前
已完结
-
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
3个月前
已完结
-
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
3个月前
已完结
-
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
3个月前
已完结
-
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
3个月前
已完结
-
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
3个月前
已完结
-
Differences in response to Der p1 and bacterial lipopolysaccharide in peripheral blood mononuclear cells from severe and non-severe asthmatics
8个月前
已关闭
-
[Recommendations for diagnosis and treatment of systemic sclerosis in China]
8个月前
已完结
-
Overexpression of programmed death ligand 1 in refractory inflammatory bowel disease
10个月前
已完结
-
原发性IgA肾病管理和治疗中国专家共识
10个月前
已完结